Have a personal or library account? Click to login
Arylsulfatase A: An Important Metabolic Factor in Pathophysiology of Different Diseases Cover

Arylsulfatase A: An Important Metabolic Factor in Pathophysiology of Different Diseases

Open Access
|Nov 2015

References

  1. 1. Barth M L, Ward C, Harris A, Saad A, Fensom A.- Frequency of arylsulphatase A pseudodeficiency associated mutations in a healthy population. J Med Genet, 1994;31:667-671.10.1136/jmg.31.9.66710500737815433
  2. 2. Ramakrishnan H, Hedayati KK. Increasing sulfatide synthesis in myelin forming cells of arylsulfatase A deficient mice causes demyelinisation and neurological symptoms reminiscent of human metachromatic leucodystophy. J Neurosci, 2007;27:9482-9490.10.1523/JNEUROSCI.2287-07.2007667312517728461
  3. 3. Takahasi T, Murakami K, et al. Sulfatide is required for efficient replication of Influenza A virus. J Virol, 2008;82:5940-5950.10.1128/JVI.02496-07239512718417587
  4. 4. Fazakas Z, Tilinca M, Nemes-Nagy E, et al. Arylsulphatase A – A possible important determinant in the pathophysiology of metabolic and neuropsychiatric diseases. Annals of RSBC, 2013;1:80-84.
  5. 5. Thomas GH. Commentary “Pseudodeficiencies” od lysosomal hydrolases. Am J Hum Genet, 1994; 54:934-940.
  6. 6. Wenger D, Louie E. Pseudodeficiencies of arylsulfatase A and galactocerebrosidase activities. Dev Neurosci, 1991;13:216-221.10.1159/0001121631687777
  7. 7. Buschard K, Blomqvist V, Osterbye T, Fredman P. Involvement of sulfatide in beta cells and type 1 and type 2 diabetes. Diabetologia, 2005;48:1957-1962.10.1007/s00125-005-1926-916143863
  8. 8. Martinelli P, Ippoliti M, Montanari M, et al. Arylsulphatase A (ASA) activity in parkinsonism and symptomatic essential tremor. ActaNeurolScand, 1994;89:171-174.10.1111/j.1600-0404.1994.tb01656.x7913281
  9. 9. Hu R, Li G, Kamijo Y. Serum sulfatides as a novel biomarker for cardiovascular disease in patients with end-stage renal failure. Glicoconj J, 2007;24:565-571.10.1007/s10719-007-9053-017657603
  10. 10. Zhang X, Nakajima T, Kamijo Y, et al. Acute kidney injury induced by protein overload nephropathy down-regulates gene expression of hepatic cerebroside sulfotransferase in mice, resulting in reduction of liver and serum sulfatides, Biochem Biophys Res Commun, 2009;390:1382-1388.
  11. 11. Han X, Holtzman D, Mckeel DW. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis, J Neurochem, 2002;82:809-818.
  12. 12. Cheng H, Xu J, McKeel DW. Specificity and potential mechanism of sulfatide deficiency in Alzheimer’s disease: an electrospray ionization mass spectrometric study, Cel Mol Biol; 2003;49:809-818.
  13. 13. Petratos S, Turnbull VJ, Papadopoulos R, Ayers M, Gonzales MF – Antibodies against peripheral myelin glycolipids in people with HIV infection. Immun Cell Biol, 1998;76:535-541.10.1046/j.1440-1711.1998.00778.x9893031
  14. 14. Purohit A, Foster PA. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. J Endocrinol. 2012;212:99-110.10.1530/JOE-11-026621859802
  15. 15. Bhattacharyya S, Tobacman JK. Steroid sulfatase, arylsulfatases A and B, galactose-6-sulfatase, and iduronate sulfatase in mammary cells and effects of sulfated and non-sulfated estrogens on sulfatase activity. J Steroid Biochem Mol Biol. 2007;103:20-34.10.1016/j.jsbmb.2006.08.00217064891
DOI: https://doi.org/10.1515/amma-2015-0064 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 233 - 235
Submitted on: Dec 9, 2014
Accepted on: Jul 18, 2015
Published on: Nov 7, 2015
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2015 Kovacs Zsolt, Tripon Robert, Nemes Nagy Eniko, Balogh Samarghitan Victor, Tilinca Mariana, Martha Orsolya, Fazakas Zita, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.